Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Cosmo Pharmaceuticals N : announces FDA Approval for Cassiopea's Winlevi, First-in-Class Topical Acne Treatment Targeting the Androgen Receptor

08/28/2020 | 08:09am EST

Dublin - Cosmo Pharmaceuticals NV announced today that Cassiopea SpA (SIX: SKIN), a company in which it holds 46.56% of the shares, today announced that the United States Food and Drug Administration (FDA) approved Winlevi for the treatment of acne in patients 12 years and older.

Notwithstanding acne being the most prevalent skin condition in the U.S. affecting up to 50 million Americans annually1, the last FDA approval of an acne drug with a new mechanism of action (MOA) occurred nearly 40 years ago.

Acne is a multifactorial skin condition, affected by four distinct pathways: excess oil (sebum) production, clogged pores (hyperkeratinization), bacteria growth (C. acnes), and inflammation2. Topical treatment options that target androgens, which largely drive sebum production and inflammation, presented a significant unmet need in the acne treatment market until now.

Cassiopea's first-in-class topical androgen receptor inhibitor, WINLEVI, tackles the androgen hormone component of acne in both males and females. Androgen receptor inhibitors act by limiting the effects of these hormones on increasing sebum production and inflammation3.

In pivotal clinical trials, WINLEVI demonstrated treatment success and reductions in acne lesions and was well tolerated when used twice a day. The most frequently observed local skin reaction was mild erythema4,5.

Diana Harbort, CEO of Cassiopea, said: 'This milestone approval marks the introduction of a new class of topical medication in Dermatology. Dermatologists have said targeting androgen hormonal activity in the skin is 'the holy grail' of acne treatment for both males and females. We are proud to bring this new innovation to acne patients and thank Cosmo Pharmaceuticals for its continued support throughout the development of this important achievement. This approval positions Cassiopea as a leader in Dermatology. Now we look forward to expanding our franchise and advancing our next investigational drug candidate for androgenetic alopecia.'

Alessandro Della Cha, CEO of Cosmo, stated: 'We congratulate the Cassiopea team on this great achievement and are proud to have been part of this. We founded Cassiopea and spun the company off listing it on the SIX in 2015. Cosmo has been supporting the development of Cassiopea through a comprehensive service agreement and has provided extensive financing.'

About Winlevi (clascoterone cream 1%)

Winlevi (clascoterone cream 1%) is approved for the treatment of acne vulgaris in people aged 12 and older. Although WINLEVI's exact mechanism of action is unknown, laboratory studies suggest the active ingredient, clascoterone, competes with androgens, specifically dihydrotestosterone (DHT), for binding to the androgen receptors within the sebaceous gland and hair follicles6.

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders and Endoscopy. The Company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, Colonic Infections and detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of its novel Artificial Intelligence device to be used in coloscopies and GI procedures. Further, Cosmo has licensed Aemcolo to Red Hill Biopharma and is the licensee for U.S. of the novel agent for procedural sedation, remimazolam, which it has sub-licensed to Acacia.


Niall Donnelly

Tel: +353 1 817 03 70

Email: ndonnelly@cosmopharma.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CASSIOPEA S.P.A. -0.65% 45.6 Delayed Quote.9.29%
COSMO PHARMACEUTICALS N.V. -0.24% 83.3 Delayed Quote.8.87%
11/24COSMO PHARMACEUTICALS N : Announces Senior Leadership Changes
11/23Cosmo Pharmaceuticals Announces Senior Leadership Changes
11/23Cosmo Pharmaceuticals kündigt Wechsel im Führungsteam an
11/20COSMO PHARMACEUTICALS N : announces expansion of agreement with Dr. Falk Pharma ..
11/19Cosmo Pharmaceuticals announces expansion of agreement with Dr. Falk Pharma f..
11/18COSMO PHARMACEUTICALS N : announces approval of Eleview in Japan
11/17Cosmo Pharmaceuticals announces approval of Eleview® in Japan
10/12COSMO PHARMACEUTICALS N : Acacia Pharma completes drawdown from EUR25 million lo..
08/28COSMO PHARMACEUTICALS N : announces FDA Approval for Cassiopea's Winlevi, First-..
08/27Cassiopea gets U.S. FDA approval for acne treatment Winlevi
More news
Sales 2020 53,1 M 63,2 M 63,2 M
Net income 2020 -8,53 M -10,2 M -10,2 M
Net cash 2020 51,0 M 60,7 M 60,7 M
P/E ratio 2020 -131x
Yield 2020 -
Capitalization 1 114 M 1 325 M 1 325 M
EV / Sales 2020 20,0x
EV / Sales 2021 16,6x
Nbr of Employees 261
Free-Float 45,8%
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 102,69 €
Last Close Price 77,00 €
Spread / Highest target 44,6%
Spread / Average Target 33,4%
Spread / Lowest Target 22,5%
EPS Revisions
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Executive Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Davide Malavasi Director-Qualified Person & Technical
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273